Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Regen BioPharma (RGBP) Interest Expenses (2016 - 2025)

Regen BioPharma (RGBP) has disclosed Interest Expenses for 12 consecutive years, with $85967.0 as the latest value for Q3 2025.

  • On a quarterly basis, Interest Expenses rose 328.49% to $85967.0 in Q3 2025 year-over-year; TTM through Dec 2025 was $132934.0, a 66.14% increase, with the full-year FY2025 number at $158286.0, up 118.49% from a year prior.
  • Interest Expenses was $85967.0 for Q3 2025 at Regen BioPharma, up from $24638.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $117984.0 in Q3 2021 to a low of $74.0 in Q1 2021.
  • A 5-year average of $28745.6 and a median of $20063.0 in 2024 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: tumbled 99.96% in 2021, then soared 57414.86% in 2022.
  • Regen BioPharma's Interest Expenses stood at $35010.0 in 2021, then crashed by 50.42% to $17359.0 in 2022, then rose by 2.45% to $17784.0 in 2023, then surged by 42.56% to $25352.0 in 2024, then soared by 239.09% to $85967.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBP's Interest Expenses are $85967.0 (Q3 2025), $24638.0 (Q2 2025), and $22329.0 (Q1 2025).